For the second quarter of 2026, analysts expect Thermo Fisher Scientific to report consensus revenue of $11.70 billion and earnings per share of $5.71, with the stock currently trading at $526.23 against a $598.00 average price target.
The primary focus for investors remains core organic revenue growth, a key metric indicating the health of the underlying life sciences business. Market participants are specifically looking for a recovery in bioprocessing demand and updates on the Clario acquisition integration following recent capital spending headwinds. Performance in the Chinese market and the academic sector will also be scrutinized for signs of stabilization as the company aims for its long-term seven percent growth target.